The Medicines Company announced that the European Commission has granted marketing authorization for two acute care products – Kengrexal (cangrelor) and Raplixa (sealant powder). These approvals follow the issuance of positive opinions in January by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

fetal pacemaker, CHLA, USC, first, fully implantable, FDA

A team of investigators at Children’s Hospital Los Angeles and the University of Southern California have developed the first fully implantable micropacemaker designed for use in a fetus with complete heart block. The team has done preclinical testing and optimization as reported in a recent issue of the journal Heart Rhythm.

AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved a new administration option for acute coronary syndrome (ACS) patients who are unable to swallow ticagrelor (Brilinta) 90 mg tablets whole. Unlike other P2Y12 inhibitors, ticagrelor has FDA approval to be crushed and administered in water by swallowing or via nasogastric tube.

Green Circle Health (GCH) announced the availability of its GCH Platform, an online patient-to-provider communications gateway. The platform enables the real-time exchange of patient vitals and health records among physicians, patients, family members and insurers. It leverages a patent-pending workflow to facilitate the collaborative sharing of data and enhance healthcare providers’ ability to proactively monitor, diagnose and treat medical conditions.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now